Compare › semaglutide vs cagrilintide
semaglutide vs cagrilintide
semaglutide is approved in the US; cagrilintide is not, and is still investigational. That is the largest single difference between them and it is easy to lose in a feature comparison. semaglutide has 429 trials on file here and cagrilintide 2, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| semaglutide | cagrilintide | |
|---|---|---|
| Status | marketed | phase3 |
| Target | GLP-1 | amylin (+GLP-1) |
| Route | SC/oral | SC |
| Sponsor | Novo Nordisk | Novo Nordisk |
| US brand names | OZEMPIC, RYBELSUS, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD | CagriSema |
| First FDA approval | 2017-12-05 | Not approved |
| EU authorisation | Ozempic, Rybelsus, Wegovy | Not authorised |
| FDA actions on file | 52 | 0 |
| Active trials | 214 | 2 |
| Active phase 3 | 75 | 2 |
| Participants enrolled | 98,857 | 630 |
| Results scheduled | 96 | 2 |
| Supply records | 3 | 0 |
Where they are being studied
Both: Obesity & overweight; Type 2 diabetes
semaglutide only: Alcohol use disorder; Atrial fibrillation; Cancer; Cardiovascular disease; Chronic kidney disease; Diabetes (unspecified); Diabetic kidney disease; Heart failure; Hypertension; MASH / NAFLD; Metabolic syndrome; Neurodegenerative disease; Obstructive sleep apnea; Polycystic ovary syndrome; Prediabetes; Psychiatric conditions; Substance use; Type 1 diabetes